Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

Inclusion Criteria:

   - Biopsy-proven prostate cancer with stable or rising PSA levels, defined as three
   consecutive PSA levels, each value greater than 1 week apart, with fluctuation between
   the three values no more than 10% downward. The third PSA needs to be within 30 days
   prior to enrollment and >= 0.1.

   - Patients may previously have been on any regimen of chemotherapy completed at least
   one month prior. Patients may be on any stable form of anti-androgen therapy.

   - Males >= age 18.

   - All patients must have a life expectancy of > 6 months.

   - Patients must have an ECOG Performance Status of <= 1

   - Patients must have no clinically significant abnormalities of organ or bone marrow
   function

   - Patients must have the ability to understand and the willingness to sign a written
   informed consent document, and the willingness/ability to comply with the protocol
   activities.

Exclusion Criteria:

   - Chemotherapy within one month prior to enrollment or plans to receive chemotherapy
   within one month after enrollment. Patients who are expected to require new or
   modified anti-androgen therapy during the course of the study are also excluded.

   - Patients may not be receiving any other Investigational Agents during the course of
   the study.

   - Patients who experience frequent symptoms of a gastrointestinal nature (e.g.,
   diarrhea, abdominal bloating, constipation or pain) are excluded.

   - Known CNS metastases.

   - Patients who, in the opinion of the Principal Investigator, have a clinically
   significant co-morbid disease that is likely to affect the ability of the patient to
   complete the trial, interfere with their ability with measurement of self-reported
   outcomes or result in adverse events unrelated to TalityTM are excluded.

   - Patients with a history of food allergy are excluded.

   - Concomitant medications necessary to treat baseline disorders are allowed (e.g.,
   hypertension, diabetes, and hyperlipidemia).

   - Patients requiring concomitant medications that, in the opinion of the Principal
   Investigator, have an unacceptable risk of adverse effects due to their nature (e.g.,
   anti-coagulant therapy, immuno-modulatory agents for autoimmune disease) must be
   excluded.

   - Pregnant or nursing patients will not be enrolled since prostate cancer is limited to
   males.

   - HIV-positive patients with active infections, HIV related cancer or poorly controlled
   viral loads must be excluded. HIV-positive patients who are stable on anti-viral
   therapy may be enrolled.